We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biosensor Platform Monitors SARS-CoV-2 Antibody Durability

By LabMedica International staff writers
Posted on 20 Oct 2021
Print article
Image: The fully automated Pylon 3-D immunochemistry system (Photo courtesy of ET HealthCare)
Image: The fully automated Pylon 3-D immunochemistry system (Photo courtesy of ET HealthCare)
Low initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers dropping to undetectable levels within months after infections have raised concerns about long-term immunity.

Seroprevalence studies have begun to show a larger extent of SARS-CoV-2 infections than initially reported because of the high prevalence of infected individuals with mild or no symptoms. However, lower SARS-CoV-2 IgG antibody levels have been reported in those with mild or no symptoms compared with those with severe COVID-19.

A team of Clinical Scientists collaborating with Weill Cornell Medicine (New York, NY, USA) developed a testing-on-a-probe “plus” panel (TOP-Plus) to include a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM, and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 5.7 weeks and 30 weeks after infection in paired samples from 80 patients with coronavirus disease 2019 (COVID-19).

Sera from individuals vaccinated for SARS-CoV-2 were also evaluated for antibody avidity. The SARS-CoV-2 TAb and SNAb assays were used to measure plasma TAb and SNAb antibodies against SARS-CoV-2. Plasma samples were assayed on the fully automated Pylon 3-D analyzer (ET HealthCare, Palo Alto, CA, USA). Bio-layer interferometry measurements (Gator Bio, Palo Alto, CA, USA) were used to compare the avidity of 12 different purified COVID-19 antibodies with the TOP-Plus avidity assay.

The investigators reported that the newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay. The imprecision of the TOP avidity assay was <10%. Although TAb and neutralization activity (by SNAb) decreased between 5.7 and 30 weeks after infection, the antibody avidity increased significantly. Antibody avidity in 10 SARS-CoV-2 vaccinated individuals (median: 28 days after vaccination) was comparable to the measured antibody avidity in infected individuals (median: 26 days after infection). No cross-reactivity was displayed in sera from patients positive for HIV, Epstein–Barr virus, or rheumatoid factor.

The authors concluded that the TOP-Plus biosensor panel is a versatile sensing platform with high precision and an ability to measure SARS-CoV-2 TAb, SNAb, and individual IgG and IgM antibody levels along with the antibody’s long-term avidity. This combination of all-in-one testing will be a valuable asset in monitoring not only patients convalescing from COVID-19, but also the status of individuals’ COVID-19 vaccination response. The study was published in the September, 2021 issue of the journal Clinical Chemistry.

Related Links:
Weill Cornell Medicine
ET HealthCare
Gator Bio

Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
Assayed Hemoglobin Control
Bench-Top Molecular Microarray System
NanoCHIP XL Analyzer
Gold Supplier
Desktop Urine Analyzer

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.